Compare AbbVie Inc (ABBV) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Schwab US Dividend Equity ETF — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while Schwab US Dividend Equity ETF trades at $32.4. The key difference: AbbVie Inc pays a 2.72% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals.
| ABBV | SCHD | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $32.83 |
52-Week Low | $184.85 | $26.38 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
SCHD trades at $32.24, down 0.46% today, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's dividend strategy is gaining attention amid rising interest in income-focused investments, with recent articles highlighting its 3.29% yield and low 0.06% expense ratio. Support and resistance levels cluster around $32-$33, indicating potential consolidation near current levels.
SCHD offers exposure to quality dividend-paying US stocks but faces mixed sentiment with some analysts citing underperformance versus broader markets. The fund's defensive positioning provides income stability, though total return comparisons with growth-oriented ETFs remain a key consideration for investors seeking balanced portfolio allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
